AI engines don’t rank your website. They rank your evidence

Zayed Yasin, MD | October 21, 2026

Roughly two thirds of physicians and three quarters of patients now turn to AI-powered search tools when researching a diagnosis. AI has even overtaken social media as a first stop for health information. Even Google — the channel industry has spent years optimizing for — now delivers an AI-generated summary as its first response, not ten blue links. The traditional digital channels life science companies rely on to reach HCPs and patients are becoming irrelevant. This structural change in how healthcare information reaches HCPs and patients demands a new strategy.

To better understand the current state of AI healthsearch, we used Writer Agent to run 40 health queries across oncology, obesity, immunology, and neurology — half patient oriented, half physician oriented. We pushed them through the top 4 consumer answer engines (Gemini/Google, ChatGPT, Perplexity & Claude), then sorted all 777 cited sources by type.

When answer engines respond to HCP questions, 19.5% of citations come from academic journals — 4x as often as in patient queries. Across both audiences, hospitals and research institutions showed around 15% of the time. The top domain for doctors is PubMed/PMC, cited 50 times. For patients, GoodRx, cited 15 times. Only one domain (fda.gov) appears in both top-8 lists. Commercial and manufacturer content is barely visible.

For companies trying to reach HCPs the implications of this pattern are profound: getting discovered means being published, a shift that will require Marketing and Medical affairs teams to work together closer than ever before.

This is not about ending existing practices completely, but rather evolving the mix. Some of the digital and web budget needs to be moved into evidence generation, and the evidence generation plan needs to be formulated with an understanding that papers will be consumed in a fundamentally different way, affecting both the breadth of publications to put out as well as structuring them to be more agent accessible.

In our work with large commercial pharma teams, we’ve found the organizational challenges to be at least as big as the technological ones — but the impact opportunity is immense.

Your healthcare marketing isn’t showing up in AI search agents

AI chatbots powered by LLM models don’t don’t work like classic Google search, which ranks pages based on hundreds of signals, including relevance, authority, and commercial content. AI search synthesizes healthcare answers from high-trust, third-party sources — peer-reviewed literature, institutional websites, reference platforms — and deprioritizes commercial and manufacturer content.

DataForSEO’s research on AI citation behavior confirms this. Their analysis found that health content is “especially citation-friendly,” and that LLMs lean toward medically authoritative sources like the CDC, Mayo Clinic, and peer-reviewed publications. Commercial domains get discovered during retrieval but rarely make it into the final cited answer for HCP-oriented content.

Ask ChatGPT about treatment pathways for metastatic melanoma. It synthesizes from published clinical literature, NCCN guidelines, and institutional pages. Not a single pharmaceutical product page appears in the cited sources. The carefully crafted manufacturer website — optimized for SEO, but which doctors never really trusted anyway — doesn’t even enter the conversation. What you’ve published on your website is mostly irrelevant, but what you’ve published in peer-reviewed journals is more impactful than ever.

Your evidence base is now your most visible asset

Medical Affairs and HEOR teams already run publication planning, congress strategies, and evidence generation — governed work built on decades of practice, guided by GPP 2022 and ICMJE standards, and protected by the regulatory firewall. The AI visibility shift doesn’t change who owns this work. It changes the strategic value of that work: when AI engines synthesize answers across the full body of literature, the evidence your medical teams produce becomes your company’s primary point of visibility with HCPs, patients, and payers — not your product pages, not your display ads, not your SEO content.

The problem is volume. When an AI engine synthesizes from hundreds of sources and your therapeutic area has a dozen papers in the mix, your evidence barely registers. The answer isn’t to commercialize publications — it’s for commercial leadership to invest more in the evidence generation that Medical Affairs and HEOR already own. That means funding more medical writers, more HEOR studies, more congress abstracts, more real-world evidence analyses — spanning the full spectrum from pivotal trial papers to supplementary analyses, systematic reviews, and economic evaluations. Conference abstracts and posters are indexed in PubMed too, adding further surface area for AI engines to find and cite.

The operating model stays the same: Medical Affairs owns the scientific decisions, commercial teams own the visibility strategy and budget advocacy. The firewall holds. What changes is that commercial leadership now has a hard business reason to fund medical affairs’ capacity — because that evidence is what shows up when a physician, patient, or payer asks an AI engine about your therapeutic area.

A portfolio approach to journal strategy

NEJM, Lancet, and JAMA reject over 95% of submissions and can take months to reach a decision. A paper there still carries weight that no AI citation count can replicate, and every medical affairs team should keep aiming for them. But a publication strategy that waits on top-tier acceptances alone produces too little indexed content, too slowly, to register in what AI engines synthesize.

Mid-ranked journals offer faster acceptance timelines, often reaching a final decision in weeks rather than months. Some offer accelerated publication tracks with peer review in under two weeks and acceptance-to-online publication in one to two weeks.

Speed matters because volume matters. The faster your content reaches the indexed literature, the sooner AI engines can find it. A bibliometric study of general medical journals found a median submission-to-acceptance time of 123 days, with significant variation across journals. Mid-ranked journals consistently sit on the faster end of that distribution. Research on author journal-choice behavior also found that prioritizing fit and speed of dissemination yields greater odds of acceptance at the first journal submitted to.

You’ll need AI to publish at this scale

The publication volume needed to influence AI answers is beyond what manual medical writing teams can realistically produce. Peer-reviewed research is explicit about the risks: hallucinated references, bias amplification, confidentiality exposure.

But the same research confirms that AI can accelerate manuscript preparation — literature discovery, citation validation, editorial refinement — without compromising scientific integrity, provided human experts remain in the loop at every stage.

A separate 2026 study found that expert reviewers couldn’t reliably distinguish AI-written from human-written abstracts. AI can produce content that reads as credible — which is exactly why peer review and MLR governance can’t be shortcut.

AI accelerates the production of draft content that human scientific experts refine and compliance teams review. The peer-review process stays intact. What changes is throughput: more content, faster, without sacrificing the scientific rigor that will earn it a justified citation when it’s accepted.

What to do next: rebalancing your budget

• Audit your current spend. How much of your marketing budget goes to channels that AI engines effectively ignore? Identify the reallocation opportunity across traditional marketing and publication strategy.
• Start with one therapeutic area. Build a publication pipeline that targets a portfolio of journals — including mid-ranked journals for faster acceptance — and includes conference presentations as additional indexed content. Support it with AI-assisted writing to achieve the volume you need.
• Measure what matters now. Traditional marketing metrics — impressions, click-through rates, page rankings — don’t capture what matters anymore. The new KPI is presence in AI-generated answers. When a physician asks OpenEvidence about your therapeutic area, does your evidence show up? When a patient asks ChatGPT about a condition you study, is your research part of the answer? This is also a field intelligence tool: your sales reps need to know what AI engines say about your therapy, because that’s the conversation they’re walking into.
• Track your share of citations over time. At WRITER, we’ve developed techniques for tracking how often you appear in the top AI search engines and how your share of voice changes over time.

Methodology: 40 health queries (20 patient-oriented, 20 physician-oriented) across oncology, obesity, immunology, and neurology were run through Gemini/Google, ChatGPT, Perplexity, and Claude with live web search enabled. All 777 cited sources were captured and sorted by source type. Full methodology available on request.